Cargando…
Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; survival in ALS is typically 3–5 years. No treatment extends patient survival by more than three months. Approximately 20% of familial ALS and 1–3% of sporadic ALS patients carry a mutation in the gene encoding superoxide dism...
Autores principales: | Borel, Florie, Gernoux, Gwladys, Cardozo, Brynn, Metterville, Jake P., Toro Cabreja, Gabriela C., Song, Lina, Su, Qin, Gao, Guang Ping, Elmallah, Mai K., Brown, Robert H., Mueller, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741242/ https://www.ncbi.nlm.nih.gov/pubmed/26710998 http://dx.doi.org/10.1089/hum.2015.122 |
Ejemplares similares
-
Evaluation of rAAVrh74 gene therapy vector seroprevalence by
measurement of total binding antibodies in patients with Duchenne muscular
dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023) -
Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis
por: Peters, Owen M, et al.
Publicado: (2018) -
An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque
por: Xu, Rui, et al.
Publicado: (2018) -
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020) -
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)